

# Dirk O Bauerschlag

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1512845/publications.pdf>

Version: 2024-02-01

60  
papers

1,528  
citations

331259

21  
h-index

329751

37  
g-index

87  
all docs

87  
docs citations

87  
times ranked

2270  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity <i>in Vitro</i> and <i>in Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2022, 21, 70-78.	1.9	1
2	High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer. <i>Cancers</i> , 2022, 14, 2.	1.7	6
3	A Giant Mammary Hamartoma in a Young Breast Cancer Patient. <i>Breast Care</i> , 2021, 16, 85-88.	0.8	2
4	Involvement of medical students in a surgery congress: impact on learning motivation, decision-making for a career in surgery, and educational curriculum. <i>Wiener Medizinische Wochenschrift</i> , 2021, 171, 182-193.	0.5	3
5	ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids. <i>Cancers</i> , 2021, 13, 2039.	1.7	17
6	Mucinous Cystic Neoplasm of Pancreas in a Pregnant Woman Presenting with Severe Anemia and Gastric Bleeding: Case Report and Review of the Literature. <i>Healthcare (Switzerland)</i> , 2021, 9, 540.	1.0	2
7	Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 90-96.	0.9	14
8	Challenges and Controversies in the Surgical Treatment of Cervical Cancer: Open Radical Hysterectomy versus Minimally Invasive Radical Hysterectomy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3761.	1.0	5
9	ADAM17 as a Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5563.	1.7	11
10	Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	3
11	Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. <i>Journal of Leukocyte Biology</i> , 2020, 107, 1081-1095.	1.5	35
12	Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses T Cell Proliferation but Not Their Cytotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 1328.	2.2	16
13	ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany. <i>Breast Care</i> , 2019, 14, 401-408.	0.8	4
14	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). <i>Anti-Cancer Drugs</i> , 2019, 30, 394-401.	0.7	3
15	SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. <i>Oncotarget</i> , 2019, 10, 6494-6508.	0.8	19
16	RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue. <i>Oncotarget</i> , 2018, 9, 32362-32372.	0.8	1
17	Quantifying cell free DNA in urine: comparison between commercial kits, impact of gender and inter-individual variation. <i>BioTechniques</i> , 2018, 64, 225-230.	0.8	31
18	Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1785-1792.	1.2	69

#	ARTICLE	IF	CITATIONS
19	Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing $\hat{3}\hat{1}$ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 814.	2.2	84
20	ADAM17 inhibition enhances platinum efficiency in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 16043-16058.	0.8	17
21	Detection and Specific Elimination of EGFR+ Ovarian Cancer Cells Using a Near Infrared Photoimmunotheranostic Approach. <i>Pharmaceutical Research</i> , 2017, 34, 696-703.	1.7	20
22	Serum cholesterol acceptor capacity in intrauterine growth restricted fetuses. <i>Journal of Perinatal Medicine</i> , 2017, 45, 829-835.	0.6	8
23	Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 303-310.	0.7	10
24	Integration and Validation of Hysteroscopy Simulation in the Surgical Training Curriculum. <i>Journal of Surgical Education</i> , 2017, 74, 84-90.	1.2	23
25	The future therapy of endometrial cancer: microRNAâ€™s functionality, capability, and putative clinical application. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 889-895.	0.8	11
26	A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1003-1011.	1.2	29
27	Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand. <i>Oncotarget</i> , 2016, 7, 54925-54936.	0.8	24
28	Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 146.	1.8	95
29	Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer. <i>Oncology</i> , 2014, 87, 300-310.	0.9	16
30	Standard of Care and Controversies in the Adjuvant Endocrine Treatment of Hormone-Responsive Early Breast Cancer. <i>Breast Care</i> , 2014, 9, 283-286.	0.8	7
31	Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. <i>European Journal of Radiology</i> , 2014, 83, 463-467.	1.2	20
32	Fulminant puerperal sepsis due to anaplastic large-cell lymphoma (ALCL) with therapy-refractory cerebral edema. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 191-193.	0.8	0
33	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 2047-2056.	1.2	28
34	Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 347-355.	1.2	5
35	Evaluation of Potentially Predictive Markers for Anti-Angiogenic Therapy with Sunitinib in Recurrent Ovarian Cancer Patients. <i>Translational Oncology</i> , 2013, 6, 305-310.	1.7	12
36	Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group. <i>Geburtshilfe Und Frauenheilkunde</i> , 2013, 73, 433-439.	0.8	4

#	ARTICLE	IF	CITATIONS
37	A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. <i>Annals of Oncology</i> , 2012, 23, 2265-2271.	0.6	72
38	Maternal and fetal cord blood lipids in intrauterine growth restriction. <i>Journal of Perinatal Medicine</i> , 2012, 40, 287-96.	0.6	68
39	Primary Pulmonary Choriocarcinoma: Case Report and Review of the Literature. <i>Gynecologic and Obstetric Investigation</i> , 2012, 74, 171-176.	0.7	35
40	The Evaluation of the Oxidative State of Low-Density Lipoproteins in Intrauterine Growth Restriction and Preeclampsia. <i>Hypertension in Pregnancy</i> , 2012, 31, 156-165.	0.5	41
41	Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer. <i>Oncology Letters</i> , 2012, 3, 530-534.	0.8	10
42	Massive Respiratory Dysfunction as Sign of Fulminant Peripartum Cardiomyopathy (PPCM). <i>Hypertension in Pregnancy</i> , 2012, 31, 451-453.	0.5	6
43	Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 603-610.	1.2	10
44	Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles. <i>Oncology</i> , 2011, 80, 12-20.	0.9	43
45	Combined treatment with TRAIL and PPAR $\gamma$ ligands overcomes chemoresistance of ovarian cancer cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 875-886.	1.2	26
46	Leiomyomatosis peritonealis disseminata in a pregnant woman. <i>Archives of Gynecology and Obstetrics</i> , 2010, 281, 123-127.	0.8	9
47	The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 79-88.	1.2	8
48	In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. <i>BMC Cancer</i> , 2010, 10, 412.	1.1	47
49	Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. <i>Anticancer Research</i> , 2010, 30, 3355-60.	0.5	17
50	One-step nucleic acid amplification—a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 203-210.	1.4	100
51	Early detection of a twin tubal pregnancy by Doppler sonography allows fertility-conserving laparoscopic surgery. <i>Archives of Gynecology and Obstetrics</i> , 2009, 279, 87-90.	0.8	9
52	Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR $\beta$ signalling. <i>Cancer Letters</i> , 2009, 273, 70-79.	3.2	28
53	Combination of Enzastaurin and Pemetrexed Inhibits Cell Growth and Induces Apoptosis of Chemoresistant Ovarian Cancer Cells Regulating Extracellular Signal-Regulated Kinase 1/2 Phosphorylation. <i>Translational Oncology</i> , 2009, 2, 164-IN1.	1.7	12
54	Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1397-1405.	1.2	26

#	ARTICLE	IF	CITATIONS
55	Anti-idiotypic antibody abagovomab in advanced ovarian cancer. <i>Future Oncology</i> , 2008, 4, 769-773.	1.1	3
56	An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 458-466.	3.2	48
57	Familial Breast Cancer, Prevention, Risk Factors and Genetics – Highlights from the San Antonio Breast Cancer Symposium (SABCS) Poster Presentations. <i>Breast Care</i> , 2006, 1, 103-106.	0.8	0
58	Benign abdominal and pulmonary metastasizing leiomyoma of the uterus. <i>Archives of Gynecology and Obstetrics</i> , 2006, 274, 319-322.	0.8	40
59	Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. <i>Oncogene</i> , 2005, 24, 1053-1065.	2.6	182
60	Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi. <i>Seminars in Cancer Biology</i> , 2003, 13, 293-300.	4.3	17